Fig. 1From: Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanomaClinical response to nivolumab and ipilimumab. a, Lung lesion before the treatment with anti-CTLA-4 and anti-PD-1 antibodies and after 8 weeks. There was a marked regression with 8 weeks of the treatement. b, After 16 weeks of treatment, a complete metabolic response was observed in the 18FDG-PET/CT scanBack to article page